Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | YH42946 |
| Synonyms | |
| Therapy Description |
YH42946 is a small molecule EGFR inhibitor with selectivity for EGFR exon 20 insertion mutations, which potentially inhibits tumor cell viability (Cancer Res (2025) 85 (8_Supplement_1): 5604). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| YH42946 | YH-42946|YH 42946 | EGFR Exon 20 Insertion Inhibitor 15 | YH42946 is a small molecule EGFR inhibitor with selectivity for EGFR exon 20 insertion mutations, which potentially inhibits tumor cell viability (Cancer Res (2025) 85 (8_Supplement_1): 5604). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06616766 | Phase Ib/II | YH42946 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | Recruiting | USA | 1 |